CD19 CAR-T + CD20 CAR-T

CD19 CAR-T + CD20 CAR-T refers to a combination of two separate chimeric antigen receptor T cell (CAR-T) therapies where T cells are genetically engineered to express chimeric antigen receptors targeting both CD19 and CD20 antigens, which are expressed on the surface of malignant B cells. These therapies are designed to enhance anti-tumor efficacy by targeting two distinct B cell markers, potentially reducing the risk of antigen escape (where the tumor loses one antigen, becoming resistant to single-antigen therapies). The mechanism involves autologous or allogeneic T cells modified to recognize either CD19 or CD20 using a single-chain variable fragment (scFv) fused to intracellular T cell activation domains. When infused, these CAR-T cells bind specifically to CD19 or CD20 on malignant B cells, causing T cell activation, cytokine release, and cytolytic killing of the targeted cells. Dual-target or combination CAR-T approaches can use either co-administration of two separately modified CAR-T cell products (CD19 CAR-T and CD20 CAR-T) or a single population of T cells modified to express both receptors. This strategy is under clinical investigation primarily in relapsed/refractory B cell malignancies, including diffuse large B cell lymphoma, chronic lymphocytic leukemia, and other B cell lymphomas[1][2][3].

Other names

dual CAR-Tbispecific CAR-Tdual-targeted CAR-T